Testing Two Different Radiation Therapy Types to See Which Is Better at Preventing Loss of Memory and Changes in Thinking Ability for People with SCLC that Has Spread to the Brain


Currently Available for Patients

 

About This Study

NRG-CC009 is a clinical study for men and women who have small cell lung cancer (SCLC) that has spread to their brain. This study compares high dose radiation therapy, called stereotactic radiosurgery (SRS), delivered only to the small areas of brain cancer to low dose whole brain radiation therapy (WBRT) that avoids the memory zone in the brain called the hippocampus. The goal of the comparison is to test whether SRS is better at preventing memory loss and changes in thinking ability. At this time, there are no clinical trials that compare WBRT that avoids the hippocampus and SRS in patients with small-cell lung cancer that has spread to the brain. Typically, patients with this type of cancer are treated with hippocampal-avoidant whole brain radiotherapy (HA-WBRT) along with memantine, a drug that helps preserve memory and thinking. Researchers want to see if treatment with SRS has less memory and thinking side effects compared to the usual treatment of hippocampal-avoidant whole brain radiotherapy (HA-WBRT) and memantine.

More information about this study is located on ClinicalTrials.gov 

 

Am I eligible for this study?

If you are over the age of 18 with small cell lung cancer that has spread to your brain, you may be able to participate. Your healthcare team is the best source for information about your treatment options, including cancer clinical trials. Be sure to take this information to your doctor to discuss your questions and concerns in general and specific to the NRG-CC009 study.

 

Are there other studies for which I might be eligible?

Please talk to your healthcare team to see if there are other clinical studies for which you may be a good fit.Click here if you would like to view a more detailed chart of other studies available.

 

Find a Study Location

Are you interested in joining the study? Find a participating location

 

Want more information?

Additional information for the NRG-CC009 study can be found in the Patient Study Brochure. Download the brochure here

 

Untitled638176106801332986

Frequently Asked Questions

Below, you can find FAQs about clinical research and this particular clinical trial.

The NRG-CC009 Study FAQ

If you are over the age of 18 with small cell lung cancer that has spread to the brain, you may be able to participate.
This study is being done to answer the following question:


Will high dose radiation therapy delivered only to the small areas of brain cancer and avoiding the surrounding normal brain tissue, called stereotactic radiosurgery (SRS), decrease side effects related to memory and thinking compared to radiation to the entire brain, called, whole-brain radiation therapy (WBRT) that avoids the hippocampus but treats all of the brain tissue along with a drug that helps preserve memory and thinking called memantine?


For patients with brain metastases from small-cell lung cancer, WBRT avoids the memory zone in the brain called the hippocampus along with a drug that helps preserve memory and thinking called memantine.


At the time of the development of this study, there have been no randomized clinical trials comparing WBRT and SRS approaches in patients with small-cell lung cancer. We are doing this study because we want to find out if the SRS approach is better.
If you decide to take part in the study, you will be randomly assigned to one of two possible study groups.


If you are assigned to treatment group 1, you will receive SRS, high dose of radiation to the small areas of cancer in the brain and avoids normal tissue.


If you are assigned to treatment group 2, you will receive the usual treatment of low dose radiation to the whole brain that avoids the hippocampus (HA-WBRT) plus the drug memantine that may decrease memory and thinking side effects.
The usual approach for patients who are not in a study is whole brain radiotherapy while avoiding the hippocampus (HA-WBRT) and while taking memantine.
If you choose to take part in this study, there is a risk that:

  • You may lose time at work or home and spend more time in the hospital or doctor’s office than usual. 
  • You may be asked sensitive or private questions which you normally do not discuss. 
  • The study approach may not be as good as the usual approach for your cancer at shrinking or stabilizing your cancer and preventing your cancer from spreading. 
  • The drugs used on this trial may cause side effects. Your doctor will review all the potential side effects with you. It is important to tell your doctor about any side effects during the study so that they may be treated and so that potential adjustments to the study drugs may be made.
There is evidence that SRS is effective in shrinking or stabilizing your type of cancer. It is not possible to know at this time if the study approach (SRS) will result in improved cognitive function compared to the usual approach (HA-WBRT with memantine).
Patients receiving SRS will receive the outpatient procedure in one day (or in some cases 2-3 days).


Patients receiving HA-WBRT will receive therapy as an outpatient for 5 days a week for 2 weeks. They will also take memantine by mouth once or twice daily for up to 6 months.
No. Taking part in this study is voluntary. You are free to choose to participate or not to participate. If you choose to participate in this study, you can leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.
You and/or your insurance plan will need to pay for the costs of medical care you get as part of the study, just as you would if you were getting the usual care for your cancer.


This includes:

  • the costs of tests, exams, procedures, and drugs that you get during the study to monitor your safety and prevent and treat side effects. 
  • the costs of SRS if you are in Group 1. 
  • the costs of HA-WBRT if you are in Group 2. 
  • your insurance co-pays and deductibles. 



Talk to your insurance provider and make sure that you understand what your insurance pays for and what it doesn’t pay for if you take part in this clinical trial. Also, find out if you need approval from your plan before you can take part in the study. 


You will not be paid for taking part in this study.

Your privacy is very important to us and the researchers will make every effort to protect it. Your information may be given out if required by law. For example, certain states require doctors to report to health boards if they find a disease like tuberculosis. However, the researchers will do their best to make sure that any information that is released will not identify you. Some of your health information and/or information about your specimens from this study will be kept in a central database for research. Your name or contact information will not be put in the database.


There are organizations that may inspect your records. These organizations are required to make sure your information is kept private, unless required by law to provide information. Some of these organizations are:


  • NRG Oncology. 
  • The National Cancer Institute (NCI) Central Institutional Review Board (CIRB), which is a group of people who review the research with the goal of protecting the people who take part in the study. 
  • The Food and Drug Administration (FDA) and the groups it works with to review research. 
  • The NCI and the groups it works with to review research, including the Cancer Trials Support Unit (CTSU). 
  • The NCI’s National Clinical Trials Network and the groups it works with to conduct research including the Imaging and Radiation Oncology Core (IROC).

Clinical Studies FAQ

Doctors and researchers conduct a clinical study, also called a “clinical trial,” to find better ways to prevent, diagnose, or treat an illness. NRG Oncology is supported by the National Cancer Institute (NCI) and runs clinical studies specifically for patients with cancer or to prevent cancer. Most clinical studies test something we know against something we don’t know. In all situations, these studies are strictly evaluated before they are allowed to be offered to any patient. The study is designed to answer the question that we do not know the answer to, so that current and future patients may have better treatments or information than what we currently have. There are different types of clinical studies that might be available for patients. For more information see Types of Clinical Trials” and “Phases of Clinical Trials”.

Patients who volunteer to take part in a clinical study are followed closely by their health care professionals and members of the research team. For more information see Research Team Members”.

Yes. They are exactly the same thing.
The care cancer doctors provide to cancer patients today is the direct result of clinical studies (also known as clinical trials) that were done in the past. Clinical studies give doctors and the treatment team information about what types of treatments work and what treatments do not work, in a number of different situations. Some studies focus on treating the cancer, others on preventing the cancer, and others on helping patients feel better or healthier during or after treatments. When you take part in a clinical study, you add to our knowledge about cancer and it may help improve cancer care for future patients. Clinical studies are available to patients with many types of cancer and at all stages of treatment. In some situations, the only way to get these new treatments is by joining a clinical study.
A clinical study may take place in many locations, such as:

  • physician offices
  • hospitals
  • clinics


  • A study is typically led by a principal investigator who is a doctor or other advanced health care professional. A clinical study is carried out by following a very specific plan known as the “protocol”. The protocol is designed so all patients in the study are treated as well as possible and in the same way. The protocol also provides rules for the doctors and clinical study staff to follow to keep patients safe and make sure the study is run in an ethical manner.
    No, not at all. Participation in a clinical study is completely voluntary. For more information see “Deciding to Take Part in a Clinical Trial”. You are free to choose to participate or not to participate. If you choose to participate in a study, you may still decide to leave the study at any time. If you decide not to participate in a study, your doctor will discuss other treatment options with you. For more information see “Questions to Ask Your Doctor about Treatment Clinical Trials".

    If you decide not to take part in a clinical study, you still have other choices. Talk to your doctor about your other choices.For example:

    • You may choose to have the usual treatment approach (known as “standard of care”)
    • You may choose to take part or learn more about a different study, if one is available
    • You may choose not to be treated for cancer

    About NRG Oncology

    At NRG Oncology, we focus on conducting clinical studies aimed to improve current cancer care practices and the lives of cancer patients. NRG Oncology partners with more than 1,300 member sites world-wide to research ways to improve treatment standards in the cancer community. Our organization is supported primarily through grants from the National Cancer Institute (NCI) and is one of five research groups in the NCI's National Clinical Trial's Network.